Development of a novel Bruton’s tyrosine kinase inhibitor that exerts anti-cancer activities potentiates response of chemotherapeutic agents in multiple myeloma stem cell-like cells
Article in Frontiers in Pharmacology (September 2022)
The most recent citing publications are shown below. View all 4 publications that cite this research output on Dimensions.
Ixazomib combined with lenalidomide and dexamethasone chemotherapy for newly diagnosed multiple myeloma in China—Compared with bortezomib/lenalidomide/dexamethasone
Article in Cancer Medicine (September 2022)
Bortezomib/melphalan/prednisone
Article in Reactions Weekly (June 2022)